146 related articles for article (PubMed ID: 34957551)
1. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
[TBL] [Abstract][Full Text] [Related]
2. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
[TBL] [Abstract][Full Text] [Related]
4. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
6. Toremifene versus tamoxifen for advanced breast cancer.
Mao C; Yang ZY; He BF; Liu S; Zhou JH; Luo RC; Chen Q; Tang JL
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008926. PubMed ID: 22786516
[TBL] [Abstract][Full Text] [Related]
7. Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
Wang H; Ma X; Zhang B; Zhang Y; Han N; Wei L; Sun C; Sun S; Zeng X; Guo H; Li Y; Zhang Y; Zhao J; Qin Z; Liu Z; Zhang N
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e148-e153. PubMed ID: 34196110
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
[TBL] [Abstract][Full Text] [Related]
9. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes.
Watanabe M; Watanabe N; Maruyama S; Kawashiro T
Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799
[TBL] [Abstract][Full Text] [Related]
10. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
12. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
[TBL] [Abstract][Full Text] [Related]
13. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Park GC; Jung JA; Bae KS; Lim HS
J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
[TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
15. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Kim J; Coss CC; Barrett CM; Mohler ML; Bohl CE; Li CM; He Y; Veverka KA; Dalton JT
Int J Cancer; 2013 Mar; 132(6):1475-85. PubMed ID: 22915089
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.
Brooks JD; Comen EA; Reiner AS; Orlow I; Leong SF; Liang X; Mellemkjær L; Knight JA; Lynch CF; John EM; Bernstein L; Woods M; Doody DR; ; Malone KE; Bernstein JL
Breast Cancer Res; 2018 Dec; 20(1):149. PubMed ID: 30526633
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
[TBL] [Abstract][Full Text] [Related]
18. Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
Gusella M; Pasini F; Corso B; Bertolaso L; De Rosa G; Falci C; Modena Y; Barile C; Da Corte Z D; Fraccon A; Toso S; Cretella E; Brunello A; Modonesi C; Segati R; Oliani C; Minicuci N; Padrini R;
Pharmacol Res Perspect; 2020 Oct; 8(5):e00646. PubMed ID: 32813313
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
Hong J; Huang J; Shen L; Zhu S; Gao W; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
BMC Cancer; 2020 Jul; 20(1):663. PubMed ID: 32677982
[TBL] [Abstract][Full Text] [Related]
20. The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.
Zeng Y; Huang K; Huang W
Pak J Pharm Sci; 2017 May; 30(3(Special)):1095-1098. PubMed ID: 28671087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]